Sandoz Launches Pemetrexed In 11 European Countries
Oncology Generic Launch Markets Include Germany, Switzerland, Netherlands And Spain
Sandoz has launched its generic pemetrexed rival to Alimta in a ready-to-dilute 1,000mg presentation in 11 EU countries including Germany, Switzerland, the Netherlands and Spain.
You may also be interested in...
Following patent expiry on 24 May, Alimta ANDA products have reached the US market, eating into a product that generated more than $1.2bn in sales last year.
Sandoz enjoyed both top- and bottom-line growth in the second quarter, as the Novartis company rebounded from a challenging Q1 and explained how it would reach its financial targets in the longer term.
Sawai is lining up eight launches as part of the Japanese company’s strategy to capture an increased share of its domestic generics market.